2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, B Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3301 Moving CAR-T forward to first remission: Real-world outcomes of inaticabtagene autoleucel as consolidation in adult B-ALL

Jin Wang, MD, PhD, Ying Wang, MD, PhD2, Er-Lie Jiang, MD3, Xin Du, MD4, Chong Wang5, Shaowei Qiu, MD6, Baohong Ping7, Pengcheng He, MD8, Suning Chen9, Yang Liang, MD, PhD10, Ping Li, PhD11, YI Ding12, Lei Fan, MD13, Jie Jin, MD14, Qike Zhang, MD15, Mingzhi Zhang, MD16, jianfen Xu17, Jian Li, MD18, Fei Li, MD, PhD19, Heng Mei, MD, PhD20, Qingxian Bai21, Peilong Lai, PhD22, Guangxun Gao23, Xiaobing Huang24, Jing Huang25, Hongsheng Zhou26
1 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Institute of Hematology & Blood Diseases Hospital, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Tianjin, China
4 The First Affiliated Hospital of Shenzhen University, Shenzhen, China
5 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
6 Institute of Hematology & Blood Diseases Hospital, Tianjin, China
7 Southern Medical University Southern Hospital, Guangzhou, China
8 The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China
9 The affiliated first hospital of Soochow University, Suzhou, China
10 Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
11 Tongji Hospital of Tongji University, Shanghai, China
12 Tongji Hospital of Tongji University, Shanghai, China
13 The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
14 The First Affiliated Hospital of Zhejiang University, Hangzhou, China
15 Gansu Provincial People's Hospital, Nanzhou, China
16 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
17 Ningbo Second Hospital, Ningbo, China
18 Peking Union Medical College Hospital, Beijing, China
19 First Affiliated Hospital of Nanchang University, Nanchang, China
20 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
21 Xijing Hospital of the Fourth Military Medical University, Xian, China
22 Guangdong Provincial People's Hospital, Guangzhou, China
23 Xijing Hospital of the Fourth Military Medical University, Xian, China
24 Sichuan academy of medical sciences & Sichuan provincial people's hospital, ChengDu, China
25 The Affiliated Guangdong Second Provincial General Hospital of Jinan university, Guangzhou, China
26 Southern Medical University Southern Hospital, Guangzhou, China

Background:The prognosis of adult B-cell acute lymphoblastic leukemia (B-ALL) remains poorer than that of pediatric patients, largely due to adverse cytogenetics, treatment-related toxicities, and limited chemotherapy tolerance. Even among patients achieving first complete remission (CR1), long-term outcomes remain suboptimal, particularly in those with high-risk cytogenetics or persistent minimal residual disease (MRD). Chimeric antigen receptor T-cell (CAR-T) therapy has substantially improved outcomes in relapsed/refractory (R/R) B-ALL; however, its application as an early consolidation strategy in CR1 has not been systematically evaluated. Inaticabtagene autoleucel (Inati-cel) is a CD19-specific CAR-T product approved in China in November 2023 for adult R/R B-ALL. In this first large, multicenter real-world study, we report the outcomes of Inati-cel as consolidation therapy in adult B-ALL patients in CR1.

Methods:This was a large, multicenter, real-world study. Eligible patients had B-ALL in CR1 and received Inati-cel as consolidation therapy after apheresis (November 7, 2023), with at least 6 months of follow-up after infusion. The primary endpoints were overall survival (OS), leukemia-free survival (LFS), and event-free survival (EFS). Secondary endpoints included minimal residual disease (MRD) negativity rate, CAR-T cell expansion and persistence, and toxicity profiles. EFS was defined as the time from CAR-T cell infusion to death, disease progression/relapse (including morphological and/or molecular relapse), or last follow-up, whichever occurred first. MRD was assessed via flow cytometry, real-time quantitative PCR (RQ-PCR), and/or next-generation sequencing (NGS). CRS and ICANS were graded per the ASTCT criteria.

Results:As of December 31, 2025, 150 patients with B-ALL in CR1 underwent apheresis, of whom 105 were evaluable. The median age was 42 years (range, 13–76), with 26.7% aged ≥60 years; 48.6% were male. Prior to CAR-T therapy, 39.0% (41/105) were MRD-positive by flow cytometry, RQ-PCR, or NGS (>10?6) at pre-apheresis and/or pre-infusion. Philadelphia chromosome-positive (Ph?) phenotype was present in 45.7% (48/105), and high-risk cytogenetic abnormalities included KMT2A rearrangement (5.7%), TP53 aberration (3.3%), Ph-like (3.3%), IKZF1 aberration (19.0%), and PAX5 alteration (3.8%). Following CAR-T infusion, all 105 patients (100%) achieved MRD negativity by flow cytometry, and 61 of 69 evaluable patients (88.4%) by PCR or NGS. CAR-T cell expansion was observed in all patients, with a median peak of 51.7 cells/μL (range, 1.64–1012) and a median persistence of 4 months (range, 1–24); the longest persistence reached 24 months post-infusion.

Notably, after a median follow-up of 14.1 months,estimated 18-month OS rate was 97.1%, 18-month LFS rate was 88.6%, and 18-month EFS rate was 71.8%.Univariate analysis identified pre-treatment MRD negativity as significantly associated with superior EFS, whereas age, cytogenetic risk, prior blinatumomab/inotuzumab exposure, CAR-T cell dose, and consolidation/maintenance therapy type were not. Multivariate Cox regression revealed that prior blinatumomab exposure was an independent adverse prognostic factor for EFS (HR 4.06, 95% CI 1.45–11.35; P<0.05), whereas CAR-T cell dose ≥1×106/kg (HR 0.36, 95% CI 0.15–0.86; P<0.05) and pre-treatment MRD negativity (HR 0.36, 95% CI 0.07–0.54; P<0.05) were independent favorable prognostic factors.

Regarding safety, any-grade CRS occurred in 52.9% of patients (1.9% grade 3), and ICANS in 2.9% (1.9% grade 3). No grade ≥4 events or treatment-related deaths were observed.

Conclusion:This first large multicenter real-world study demonstrates that Inati-cel as consolidation therapy in adults with B-ALL in CR1 achieves high MRD negativity rates, excellent 18-month survival, and a favorable safety profile. Pre-treatment MRD negativity and CAR-T cell dose ≥1×106/kg were identified as independent favorable prognostic factors for EFS, whereas prior blinatumomab exposure was an independent adverse factor. These findings support Inati-cel as a promising consolidation strategy in CR1 and provide a rationale for patient selection and dose optimization. Extended follow-up and prospective studies are warranted to validate these observations.

Jin Wang, MD, PhD: No relevant conflicts of interest to declare.